Eric Lander - Infinity Pharmaceuticals Independent Director
INFIDelisted Stock | USD 0.04 0.03 42.86% |
Director
Dr. Eric S. Lander Ph.D. is Independent Director of Infinity Pharmaceuticals Inc. since September 2006. Dr. Lander was a cofounder and a member of the board of directors of Infinity Discovery Inc. from 2001 until the time of its merger with our predecessor company in September 2006. Dr. Lander was a Professor and Associate Professor of Biology at the Massachusetts Institute of Technology or MIT since 1990 and a Professor of Systems Biology at HMS since 2004. Dr. Lander has served as the founding Director of The Eli and Edythe L. Broad Institute a biomedical research institute formed by MIT and Harvard University since 2003. Dr. Lander currently serves as a director of Innocence Project a notforprofit legal clinic and as cochair of the United States Presidents Council of Advisers on Science and Technology. From 1993 to 2003 Dr. Lander was the director of the WhiteheadMIT Center for Genome Research since 2006.
Age | 57 |
Tenure | 18 years |
Professional Marks | Ph.D |
Phone | 617 453 1000 |
Web | https://www.infi.com |
Infinity Pharmaceuticals Management Efficiency
The company has return on total asset (ROA) of (0.607) % which means that it has lost $0.607 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (35.2135) %, meaning that it created substantial loss on money invested by shareholders. Infinity Pharmaceuticals' management efficiency ratios could be used to measure how well Infinity Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities.The company currently holds 917 K in liabilities with Debt to Equity (D/E) ratio of 0.13, which may suggest the company is not taking enough advantage from borrowing. Infinity Pharmaceuticals has a current ratio of 4.08, suggesting that it is liquid enough and is able to pay its financial obligations when due. Debt can assist Infinity Pharmaceuticals until it has trouble settling it off, either with new capital or with free cash flow. So, Infinity Pharmaceuticals' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Infinity Pharmaceuticals sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Infinity to invest in growth at high rates of return. When we think about Infinity Pharmaceuticals' use of debt, we should always consider it together with cash and equity.
Similar Executives
Showing other executives | DIRECTOR Age | ||
Patrick Machado | Chimerix | 54 | |
Lisa Ricciardi | Chimerix | 57 | |
William LaRue | TRACON Pharmaceuticals | 66 | |
Wayne Kauth | Instil Bio | 79 | |
Martha Demski | Chimerix | 65 | |
Ted Wang | TRACON Pharmaceuticals | 50 | |
Fred Middleton | Chimerix | 67 | |
Alfred Scheidegger | TRACON Pharmaceuticals | 58 | |
George Rohlinger | Instil Bio | N/A | |
Gaggar | Instil Bio | 85 | |
Veena Hingarh | Instil Bio | N/A | |
Frederick Gluck | CytomX Therapeutics | 82 | |
Joseph Schepers | Chimerix | 58 | |
Fiona Oliver | Instil Bio | N/A | |
Marion McCourt | CytomX Therapeutics | 58 | |
Susan Mahony | Assembly Biosciences | 52 | |
Matthew Young | CytomX Therapeutics | 49 | |
Anne Urlwin | Instil Bio | N/A | |
Roger Loeb | Instil Bio | N/A | |
David Jakeman | Chimerix | 41 | |
John Scarlett | CytomX Therapeutics | 67 |
Management Performance
Return On Equity | -35.21 | |||
Return On Asset | -0.61 |
Infinity Pharmaceuticals Leadership Team
Elected by the shareholders, the Infinity Pharmaceuticals' board of directors comprises two types of representatives: Infinity Pharmaceuticals inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Infinity. The board's role is to monitor Infinity Pharmaceuticals' management team and ensure that shareholders' interests are well served. Infinity Pharmaceuticals' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Infinity Pharmaceuticals' outside directors are responsible for providing unbiased perspectives on the board's policies.
Joseph Pearlberg, Vice President - Clinical Development | ||
Melissa Hackel, Vice President - Finance | ||
William Bertrand, Executive Vice President General Counsel | ||
Vito Palombella, Chief Scientific Officer and Executive VP | ||
Jeffrey Berkowitz, Independent Director | ||
Seth JD, Chief VP | ||
Lawrence Bloch, CFO, Executive Vice President Chief Business Officer | ||
Norman Selby, Lead Outside Independent Director | ||
Jose Baselga, Independent Director | ||
Samuel Agresta, Chief Medical Officer | ||
Michael Venuti, Independent Director | ||
Stephane Peluso, Chief Officer | ||
MD Ilaria, Chief Officer | ||
Jayne Kauffman, Sr Coordinator | ||
Michael Kauffman, Independent Director | ||
Eric Lander, Independent Director | ||
David Beier, Independent Director | ||
Julian Adams, President of RandD | ||
Anthony Evnin, Independent Director | ||
Gwendolyn Fyfe, Independent Director | ||
Sujay Kango, Executive Vice President Chief Commercial Officer | ||
Ian Smith, Independent Director | ||
Adelene Perkins, Chairman of The Board, CEO and Pres | ||
MD JD, Pres Treasurer |
Infinity Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Infinity Pharmaceuticals a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Return On Equity | -35.21 | |||
Return On Asset | -0.61 | |||
Operating Margin | (15.70) % | |||
Current Valuation | (9.46 M) | |||
Shares Outstanding | 90.76 M | |||
Shares Owned By Insiders | 2.36 % | |||
Shares Owned By Institutions | 23.48 % | |||
Number Of Shares Shorted | 2.21 M | |||
Price To Earning | (1.63) X | |||
Price To Book | 8.03 X |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Risk vs Return Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in census. Note that the Infinity Pharmaceuticals information on this page should be used as a complementary analysis to other Infinity Pharmaceuticals' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the AI Investment Finder module to use AI to screen and filter profitable investment opportunities.
Other Consideration for investing in Infinity Stock
If you are still planning to invest in Infinity Pharmaceuticals check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Infinity Pharmaceuticals' history and understand the potential risks before investing.
Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity | |
Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios | |
ETFs Find actively traded Exchange Traded Funds (ETF) from around the world | |
Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
Bonds Directory Find actively traded corporate debentures issued by US companies | |
CEOs Directory Screen CEOs from public companies around the world |